RANCHO CUCAMONGA, Calif., May 03, 2018 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018, after the market closes on Wednesday, May 9, 2018, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 5298899.
The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.
Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, the timing for completion of construction at the Company’s IMS facility, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission.
Contact:
William J. Peters
Chief Financial Officer
(909) 980-9484


Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 



